| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
BMS-908662 manufacturers
- Xl-281
-
- $293.00
-
2026-07-27
- CAS:870603-16-0
- Purity: 99.12%
- Supply Ability: 10g
|
| | BMS-908662 Basic information |
| Product Name: | BMS-908662 | | Synonyms: | BMS-908662;Carbamic acid, N-[6-[2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl]-1H-benzimidazol-2-yl]-, methyl ester;BMS-908662(1X-281) | | CAS: | 870603-16-0 | | MF: | C24H19ClN4O4 | | MW: | 462.89 | | EINECS: | | | Product Categories: | | | Mol File: | 870603-16-0.mol |  |
| | BMS-908662 Chemical Properties |
| density | 1.526±0.06 g/cm3(Predicted) | | pka | 10.77±0.20(Predicted) |
| | BMS-908662 Usage And Synthesis |
| Uses | XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity[1]. | | IC 50 | c-Raf: 2.6 nM (IC50); B-Raf: 4.5 nM (IC50); B-RafV600E: 6 nM (IC50) | | References | [1] Dickson MA, et al., Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):349-56. DOI:10.1007/s10637-014-0191-5 |
| | BMS-908662 Preparation Products And Raw materials |
|